A multi-institutional retrospective study of osimertinib for elderly patients with previously untreated advanced non-small cell lung cancer harboring EGFR mutations (HOT2002)
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000044101
- Lead Sponsor
- Hokkaido Lung Cancer Clinical Study Group(HOT)
- Brief Summary
This study investigated the effects of osimertinib in 132 elderly non-small cell lung cancer patients aged 75 or older. The 1-year progression-free survival rate was 65.8%, with a median duration of 19.4 months. 17.4% of patients experienced severe pneumonitis, mostly within three months of treatment initiation. While osimertinib is effective, there's a notable risk of pneumonitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who had received other EGFR-TKIs before receiving osimertinib were excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the proportion of patients who were progression-free survival at 1 year (1-year PFS)
- Secondary Outcome Measures
Name Time Method safety profile, objective response rate (ORR), disease control rate (DCR), PFS, and overall survival (OS)